ReviewBioMed research international2023
Niosome as an Effective Nanoscale Solution for the Treatment of Microbial Infections.
Review in BioMed research international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 38 citations in OpenAlex.
- Niosomal delivery of cefoxitin enhances antibacterial and antibiofilm activities against gram-positive and gram-negative bacteria.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Nano-antimicrobial peptides (Nano-AMPs) to combat resistant gram-negative bacteria.Drug delivery and translational research · 2026Review
- Mechanistic evaluation of niosomal Rhoifolin in antileishmanial therapy and its additive potential with meglumine antimoniate.Scientific reports · 2026Article
- Article
- Enhanced Antimicrobial Activity of Ciprofloxacin Encapsulated in Sophorolipid-Based Nano-Assemblies Against Ciprofloxacin-/Methicillin-ResistantPharmaceutics · 2026Article
- Platelet-rich plasma-contained drug delivery systems to treat orthopedic injuries.International journal of pharmaceutics: X · 2025Review
- Development of Vancomycin, a Glycopeptide Antibiotic, in a Suitable Nanoform for Oral Delivery.Molecules (Basel, Switzerland) · 2025Article
- Formulation and characterization of BBR loaded niosomes using saponin as a nonionic biosurfactant investigating synergistic effects to enhance antibacterial activity.Scientific reports · 2025Article
- Polymeric Molecular Envelope Technology for Improved Therapeutics Efficacy: A Review.Current medicinal chemistry · 2025Review
- Multifunctional poloxamer-based thermo-responsive hydrogel loaded with human lactoferricin niosomes:International journal of pharmaceutics: X · 2024Article
- Comparative efficacy ofPeerJ · 2024Article
- Topical bismuth oxide-manganese composite nanospheres alleviate atopic dermatitis-like inflammation.Journal of nanobiotechnology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Numerous disorders go untreated owing to a lack of a suitable drug delivery technology or an appropriate therapeutic moiety, particularly when toxicities and side effects are a major concern. Treatment options for microbiological infections are not fulfilled owing to significant adverse effects or extended therapeutic options. Advanced therapy options, such as active targeting, may be preferable to traditional ways of treating infectious diseases. Niosomes can be defined as microscopic lamellar molecules formed by a mixture of cholesterol, nonionic surfactants (alkyl or dialkyl polyglycerol ethers), and sometimes charge-inducing agents. These molecules comprise both hydrophilic and hydrophobic moieties of varying solubilities. In this review, several pathogenic microbes such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.